Notwithstanding positive clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial difficulty from pharmacy benefit managers. Such organizations are often creating limitations to coverage, such as steep expense rest